Inovio Pharmaceuticals (INO) Stock Statistics & Valuation Metrics

Inovio Pharmaceuticals has a market cap or net worth of $81.05M. The enterprise value is -$28.57B.

Inovio Pharmaceuticals has 36,674,435 shares outstanding. The number of shares has decreased by -2.65% in one year.

Inovio Pharmaceuticals’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -0.14%.

The current PE Ratio of Inovio Pharmaceuticals is -0.46. Inovio Pharmaceuticals’s PEG ratio is -0.02.

In the last 12 months, Inovio Pharmaceuticals had revenue of 217.76K and earned -107.25M in profits. Earnings per share was -3.95.

In the last 12 months, operating cash flow was -111.28B and capital expenditures 35.58K, giving a free cash flow of -111.28B billion.

Inovio Pharmaceuticals pays an annual dividend of $0.069, resulting in a dividend yield of ―

Inovio Pharmaceuticals upcoming earnings date is Aug 6, 2025, TBA (Confirmed).

Inovio Pharmaceuticals as a current ratio of 2.77, with Debt / Equity ratio of 21.99%

In the past 12 months, Inovio Pharmaceuticals has paid -107.15B in taxes.

Inovio Pharmaceuticals EV to EBITDA ratio is 518.52, with an EV/FCF ratio of 515.46.

Inovio Pharmaceuticals has $68.36B in cash and marketable securities with $11.27B in debt, giving a net cash position of -$57.09B billion.

Gross margin is -636.81%, with operating margin of -51616.91%, and net profit margin of -49254.27%.

The average price target for Inovio Pharmaceuticals is $8.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy